Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Phase II, Single Center Study of Oral Forodesine in Patients with Advanced, Fludarabine-Treated Chronic Lymphocytic Leukemia (CLL).

Dushyant Verma, MD, FACP, Kumudha Balakrishnan, PhD, Susan O'Brien, MD, Deborah A. Thomas, MD, Alessandra Ferrajoli, MD, William G. Wierda, MD, PhD, Amit Verma, MD, Stefan Faderl, MD, Susan M Bickel, Shanta Bantia, PhD, Hagop M Kantarjian, MD, Michael J. Keating, MBBS, Varsha Gandhi, PhD, Farhad Ravandi, MD

Blood (2009) 114 (22): 2369.

https://doi.org/10.1182/blood.V114.22.2369.2369

Published: 2009

Journal Articles

In-Vitro Efficacy of the Deoxyguanoside Analogs Forodesine (BCX-1777) and ARA-G in Pediatric Acute Lymphoblastic Leukemia.

Irene Homminga, MD, Michel C. Zwaan, MD, PhD, Amel Seghouani, MD, Chantal Y. Manz, PhD, Shanta Bantia, PhD, Wilco Smits, Rob Pieters, MD, PhD, Jules P.P. Meijerink, PhD

Blood (2009) 114 (22): 2038.

https://doi.org/10.1182/blood.V114.22.2038.2038

Published: 2009

Journal Articles

In-Vitro Efficacy of the Deoxyguanoside Analogs Forodesine (BCX- 1777) and ARA-G in Pediatric Acute Lymphoblastic Leukemia Cells.

Irene Homminga, MD, Christian M Zwaan, MD, PhD, Chantal Y. Manz, PhD, Shanta Bantia, PhD, Cynthia Parker, Jessica Buijs-Gladdines, Wilco Smits, Martin A. Horstmann, MD, Rob Pieters, MD, PhD, Jules P.P. Meijerink, MSc, PhD

Blood (2008) 112 (11): 1925.

https://doi.org/10.1182/blood.V112.11.1925.1925

Published: 2008

Journal Articles

A Phase II Study of the Purine Nucleoside Phosphorylase (PNP) Inhibitor RO5092888 (BCX-4208) in Patients with Moderate to Severe Chronic Plaque Psoriasis: Safety, Tolerability and Lymphocyte Effects

Joseph P Gomes, PharmD, MS, BCPS, Angela Georgy, Sharon Passe, Adrienne Farid, Shanta Bantia, PhD, Gerhard Wolff

Blood (2008) 112 (11): 2583.

https://doi.org/10.1182/blood.V112.11.2583.2583

Published: 2008

Journal Articles

Forodesine (Immucillin H, BCX-1777) Shows Activity on Mantle Cell Lymphoma Primary Cells

Andrea Rinaldi, Emilia Ceresa, Davide Rossi, Gianluca Gaidano, Shanta Bantia, PhD, Chantal Y. Manz, PhD, Carlo Catapano, Emanuele Zucca, Francesco Bertoni, MD

Blood (2008) 112 (11): 4997.

https://doi.org/10.1182/blood.V112.11.4997.4997

Published: 2008

Journal Articles

BCX-4208 (RO5092888), a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Is a Novel, Potent Orally Active Anti-T-Cell and B-Cell Agent.

Shanta Bantia, PhD, Cynthia Parker, Ramanda Upshaw, John Michael Kilpatrick, PhD, Amanda Cunningham, Jianwen Zhang, PhD, Pravin Kotian, PhD, Philip Morris, PhD, Pooran Chand, PhD, Yarlagadda S. Babu, PhD

Blood (2008) 112 (11): 1547.

https://doi.org/10.1182/blood.V112.11.1547.1547

Published: 2008

Journal Articles

The Purine Nucleoside Phosphorylase Inhibitor Forodesine (BCX-1777) Is a Potent Cytotoxic Agent and Has Synergistic Activity with Bendamustine in Chronic Lymphocytic Leukemia (CLL) Irrespective of ZAP-70 Levels and p53 Status.

Roberto Alonso, PhD, Neus Villamor, MD, Ramanda Upshaw, BS, Shanta Bantia, PhD, Thomas Mehrling, MD, Elias Campo, MD, Emili Montserrat, MD, Dolors Colomer, PhD

Blood (2007) 110 (11): 3122.

https://doi.org/10.1182/blood.V110.11.3122.3122

Published: 2007

Journal Articles

Phase I/II Study of Oral Fodosine TM , a PNP Inhibitor in Refractory Cutaneous T-Cell Lymphoma Patients.

Madeleine Duvic, MD, Debra Breneman, MD, Maureen Cooper, MD, Gustavo Fonseca, MD, J. Claude Bennett, MD, J. Michael Kilpatrick, PhD, Shanta Bantia, PhD

Blood (2005) 106 (11): 2683.

https://doi.org/10.1182/blood.V106.11.2683.2683

Published: 2005

Journal Articles

Forodesine (Fodosine TM ), a PNP Inhibitor Active in Relapsed or Refractory T-Cell Leukemia Patients (Phase II Study).

Richard R. Furman, MD, Genadi Iosava, MD, Luis Isola, MD, Farhad Ravandi, MD, Mamia Zodelava, MD, J. Claude Bennett, MD, J. Michael Kilpatrick, PhD, Shanta Bantia, PhD, Fodosine Development Group

Blood (2005) 106 (11): 881.

https://doi.org/10.1182/blood.V106.11.881.881

Published: 2005

Journal Articles

Antileukemic Activity and Pharmacodynamics of Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, in Phase I/II Trials in Patients with Advanced T-Cell Malignancies.

Luis Isola, MD, Richard R. Furman, MD, Varsha Gandhi, PhD, Deborah A. Thomas, MD, J. Claude Bennett, MD, Shanta Bantia, PhD, J. Michael Kilpatrick, PhD

Blood (2004) 104 (11): 4501.

https://doi.org/10.1182/blood.V104.11.4501.4501

Published: 2004

Journal Articles

Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Patients with Refractory Cutaneous T-Cell Lymphoma.

Madeleine Duvic, MD, Francine M. Foss, MD, Elise A. Olsen, MD, Andres Forero-Torres, MD, J. Claude Bennett, MD, Shanta Bantia, PhD, J. Michael Kilpatrick, PhD

Blood (2004) 104 (11): 2491.

https://doi.org/10.1182/blood.V104.11.2491.2491

Published: 2004

Journal Articles

Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Phase I/II Studies in Patients with B-Cell Acute Lymphoblastic Leukemia.

Richard R. Furman, MD, Varsha V. Gandhi, PhD, J. Claude Bennett, MD, Shanta Bantia, PhD, J. Michael Kilpatrick, PhD

Blood (2004) 104 (11): 2743.

https://doi.org/10.1182/blood.V104.11.2743.2743

Published: 2004

NARROW

Phase II, Single Center Study of Oral Forodesine in Patients with Advanced, Fludarabine-Treated Chronic Lymphocytic Leukemia (CLL).

In-Vitro Efficacy of the Deoxyguanoside Analogs Forodesine (BCX-1777) and ARA-G in Pediatric Acute Lymphoblastic Leukemia.

In-Vitro Efficacy of the Deoxyguanoside Analogs Forodesine (BCX- 1777) and ARA-G in Pediatric Acute Lymphoblastic Leukemia Cells.

A Phase II Study of the Purine Nucleoside Phosphorylase (PNP) Inhibitor RO5092888 (BCX-4208) in Patients with Moderate to Severe Chronic Plaque Psoriasis: Safety, Tolerability and Lymphocyte Effects

Forodesine (Immucillin H, BCX-1777) Shows Activity on Mantle Cell Lymphoma Primary Cells

BCX-4208 (RO5092888), a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Is a Novel, Potent Orally Active Anti-T-Cell and B-Cell Agent.

The Purine Nucleoside Phosphorylase Inhibitor Forodesine (BCX-1777) Is a Potent Cytotoxic Agent and Has Synergistic Activity with Bendamustine in Chronic Lymphocytic Leukemia (CLL) Irrespective of ZAP-70 Levels and p53 Status.

Phase I/II Study of Oral Fodosine TM , a PNP Inhibitor in Refractory Cutaneous T-Cell Lymphoma Patients.

Forodesine (Fodosine TM ), a PNP Inhibitor Active in Relapsed or Refractory T-Cell Leukemia Patients (Phase II Study).

Antileukemic Activity and Pharmacodynamics of Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, in Phase I/II Trials in Patients with Advanced T-Cell Malignancies.

Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Patients with Refractory Cutaneous T-Cell Lymphoma.

Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Phase I/II Studies in Patients with B-Cell Acute Lymphoblastic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only